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Background: Zoliflodacin (topoisomerase II inhibitor) and solithromycin (first 
fluoroketolide) are new drugs that are in clinical development for the treatment of 
uncomplicated gonorrhea. In this study, we determined the in vitro activity of zoliflodacin 
and solithromycin in gonococcal isolates from the Republic of Korea. 
Methods: A total of 250 isolates of N. gonorrhoeae collected throughout the Republic of 
Korea from 2016 to 2018 were tested to determine the MIC of therapeutic antimicrobials 
using the CLSI agar dilution method.  
Results: Most isolates (86.4%, 234/250) were non-susceptible to penicillin G, tetracycline, 
and ciprofloxacin, but all isolates were susceptible to ceftriaxone and spectinomycin. The 
MIC range for zoliflodacin and solithromycin were ≤0.015–0.12 mg/L and ≤0.015–0.5 
mg/L, respectively. MIC50 and MIC90 were 0.03 and 0.06 mg/L for zoliflodacin and 0.06 
and 0.12 mg/L for solithromycin. All isolates belonged to the wild-type MIC distribution 
for zoliflodacin, and there were no cross-resistance between zoliflodacin and ciprofloxacin 
(also a topoisomerase II inhibitor). The azithromycin-resistant isolate with the highest MIC 
of azithromycin (32 mg/L) had the highest MIC of solithromycin (0.5 mg/L), illustrating 
cross-resistance between azithromycin and solithromycin at higher MICs. 
Conclusion: Zoliflodacin and solithromycin showed potent antimicrobial activity against 
contemporary multidrug-resistant N. gonorrhoeae isolates in the Republic of Korea. 
However, the recently finished phase III clinical trial for solithromycin identified relatively 
xi 
 
many treatment failures. Zoliflodacin remains more promising, and a multi-continental 
phase III clinical trial will be initiated in 2019. 




1.1.  Background 
Neisseria gonorrhea is a species of Gram-negative diplococci bacteria that was isolated by 
Albert Neisser in 1879, also known as gonococcus (singular), or gonococci (plural). 
Gonorrhea is a sexually transmitted infection (STI) caused by Neisseria gonorrhea 
(gonococcus), one of the world's most chronic and intimidating sexually transmitted 
diseases, and is a significant public health concern worldwide. 
For Neisseria gonorrhea, the sexually transmitted disease gonorrhea agent, humans are the 
only natural host. Gonorrhea is an acute pyogenic infection of the non-conciliated columnar 
and transitional epithelium; infection can be discovered wherever these cells are 
discovered. Gonococcal infections are mostly acquired through sexual contact and occur 
primarily in the urethra, endocervix, anal canal, pharynx, and conjunctiva [25]. The most 
common types of infection are acute urethritis in men and endocervicitis in 
women. Most untreated infections resolve spontaneously after several weeks, but serious 
complications such as pelvic inflammatory diseases and gonococcal infections can occur. 
People who often have unhealthy sex habits such as having multiple sex partners are at 
high risk of contracting gonorrhea. Besides, the bacteria that cause gonorrhea can directly 
infect open wounds in the oral mucosa [7]. Gonorrhea can be spread through everyday 
items such as towels, underwear. Moreover, gonorrhea can be transmitted through blood 
transfusions that cannot guarantee the principles of sterility and safety in the process, or 
through performing medical procedures that are not sterile, not sterilized [7] [25]. 
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WHO announced a global action plan to control gonococcal AMR's spread and influence 
around the world in 2012 [53] [27]. Simultaneously, WHO Global Health Sector Strategy 
on Sexually Transmitted Infections was endorsed by the United Nations (UN) World 
Health Assembly, from 2016–2021, in which one of the significant targets is a 90% 
reduction in the incidence of gonorrhea globally [51].  
In South Korea, There have been many studies carried out in South Korea since the 90s 
[22];  Moreover, gonorrhea has been prevalent among specific patient groups; findings 
from 2004 suggest that the disease is concentrated among young people in shelters. At the 
same time, the incidence of gonorrhea in college students with high sexual activity is 28% 
[23]. In Korea, antimicrobial resistance in N. gonorrhea in recent years has been a severe 
problem. However, no comprehensive antibiotic resistance data for cultured strains after 
2006 has been published internationally [17]. Both spectinomycin and ceftriaxone have 
been used to treat gonococcal infections primarily as monotherapy before 2011. However, 
dual antimicrobial therapy (250 mg of ceftriaxone plus 1 g of azithromycin or 250 mg of 
ceftriaxone plus 100 mg of doxycycline twice daily for seven days) was implemented as 
the recommended first-line therapy for uncomplicated gonococcal infections in the 2011 
Korean guideline [16].  The elevated selective pressure arising from extensive use can lead 
to resistance growth. Accordingly, quality-assured domestic and global monitoring of 
antimicrobial resistance is crucial to define the emerging resistance, resistance patterns, 




1.2.  History and evidence of antibiotic-resistant N. gonorrhoeae 
Not long after the first antimicrobials (sulfonamides) started to be used for the treatment of 
gonorrhea, AMR in N. gonorrhoeae was detected at the beginning of the 20th century. N. 
gonorrhoeae has continually presented an extreme capacity to develop resistance to all 
antimicrobials introduced for continuing the treatment.  
 
Figure 1: History of antimicrobial and resistance in Neisseria gonorrhoea [47] 
Factors that contribute to increased resistance include suboptimal diagnostic and 
surveillance ability, simple antibiotic accessibility (including counterfeit drugs), and 
absence of drug quality control, which adds to the fast growth of resistance. Resistance has 
extended to include penicillin, tetracyclines, macrolides (including azithromycin), 
sulphonamides and combinations of trimethoprim, quinolones, and, more recently, a few 
isolated strains of cephalosporins [52]. Highly variable N. gonorrhoeae strains are widely 
antimicrobial-resistant, and gonorrhea has consistently jeopardized gonorrhea management 
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and control. Clinicians resort to empirical treatment for gonorrhea due to extensive AMR, 
the persistence of AMR determinants in gonococci, and the unavailability of diagnostic 
exams that provide AMR outcomes at the moment of therapy. Resistance to 
sulphonamides, penicillin, tetracyclines, macrolides, fluoroquinolones, and early-
generation cephalosporins has appeared rapidly since antimicrobial therapy was 
introduced. Currently, ceftriaxone is the only surviving empirical monotherapy for 
gonorrhea injectable extended-spectrum cephalosporin (ESC) in most nations. Currently, 
in many countries were conducted gonococcal in vitro resistance and surveillance to 
treatment failures in the therapy of the last-line oral ESC cefixime and ceftriaxone have 
been checked but rarely meeting [53] [47] [38] [39] [45].  
 
Figure 2: Countries reporting antimicrobial resistance to extended-spectrum 
cephalosporins [49] 
Currently, the only first-line antimicrobials suggested for empirical treatment of 
uncomplicated gonorrhea in many nations are extended-spectrum cephalosporins. The 
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incidence of isolates with decreased susceptibility to cefixime (CFM) in the United States 
has led to dual therapy with ceftriaxone plus azithromycin or doxycycline being the only 
suggested therapy regimen by Centers for Disease Control and Prevention (CDC) [50]. So 
far, there have not been any new antibiotics approved to treat gonorrhoea for many years, 
and whereas the world, appearing in the first three cases of infection with extensively drug-
resistance (XDR) Neisseria gonorrhoeae resistant to azithromycin and with ceftriaxone, 
would have a significant public health impact [2] [9] [15]. In the recent decades, several 
new antimicrobials were introduced with the intention of being patented as medications 
against gonorrhea in the context of gonorrhea becoming more resistant to medications 
currently being administered for treatment throughout the world. Some of them are 
solithromycin and zoliflodacin. In 2018, efficacy data on zoliflodacin, solithromycin, and 
gepotidacin. New medications for the treatment of uncomplicated gonorrhoea, were 
released [26] [35]. 
1.3.  Aim of the study 
This study aimed (1) to investigate in-vitro susceptibility to zoliflodacin and solithromycin 
against a collection of N. gonorrhea isolates. The susceptibility was compared to the 
susceptibility to antimicrobials previously and currently used for the treatment of gonorrhea 
(penicillin G, ceftriaxone, cefixime, spectinomycin, gentamycin, tetracycline, 
azithromycin, and ciprofloxacin). (2) to perform to molecular epidemiology N. 
gonorrhoeae multiantigen sequence typing (NG-MAST), and multi-locus sequence typing 
(MLST) in all isolates. 
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II. Literature Review 
2.1.  Epidemiology of Neisseria gonorrhoeae infection. 
Considering that gonorrhoea is one of the most prevalent STIs globally, the World Health 
Organization (WHO), estimated 87 million fresh instances in 2016 [52], the absence of 
efficient therapy would result in a significant public health problem. It is the second most 
reported transmissible disease in the United States and the second most common sexually 
transmitted infection (STI).  
WHO reported 106 million new cases of gonorrhea in adults worldwide in 2008, an 
alarming number of truly urgent risks worldwide. The situation was an increase of 21 per 
cent relative to 2005. The highest estimates are 42.0 million cases, 25.4 million cases, and 
21.1 million cases, respectively, in the WHO Western Pacific Region, WHO Southeast 
Asia Region, WHO Africa Region. In 2012, the World Health Organization (WHO) 
continued to estimate that there were 78 million cases among adults worldwide, including 
35.2 million, 11.4 million, 11.4 million, 11 million, 4.7 million cases, respectively, in the 
WHO Western Pacific Region, the African Region, the Americas Region, the European 
Region, and the Eastern Mediterranean Region [28].  N. Gonorrhea is caused by gonorrhea, 
which spreads mainly through sexual activities and penetrates through open wounds or thin 
skin and mucous membranes in the mouth. Most people who suffer from gonorrhea are 
often associated with people who have the disease. Especially the disease is extremely 
contagious when having unsafe sex; even if uses condom, the possibility of infection is still 
very high. This is explained by experts that when having sex; there will be rubbing due to 
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the copulatory movements, causing damage of the vital area. The enclosed area with many 
blood vessels and contains relatively thin mucosa, making it very susceptible to infection. 
In a published report of PLOS Medicine (2017), about 78 million people suffer from 
gonorrhea each year, including 35.2 million in the Western Pacific region, 11.4 million in 
Southeast Asia, 11.4 million in Africa, 11 million in the Americas, 4.7 million in Europe 
and 4.5 million in the Eastern Mediterranean region [48]. 
In 2017, CDC accounted for over 555,000 gonorrhea outbreaks, making it the second most 
common notifiable disease in the U.S. It is revealed that gonorrhea levels increased 75.2 
per cent from the extraordinary low in 2009 and grew 18.6 per cent from 2016 onwards. 
Antimicrobial resistance in the treatment of gonorrhea remains a significant issue. 
Ccurrently, CDC has recommended a primary therapy for the disease, ceftriaxone and 
azithromycin therapy. Since 2008, the proportion of isolates with high minimum 
ceftriaxone inhibitory levels (MICs) has remained low and was only 0.2% in 2017. The 
number of isolates with elevated MICs of azithromycin increased from 2.5% to 4.4% 
during 2014–2017 [5]. 
South Korean’s neighbors also issued warnings about the country's incidence of gonorrhea. 
Every year, China reports about 115,000 fresh gonorrhea instances. Gonorrhea have risen 
in recent years and became one of the country's most surveilled infectious diseases [54]. 
Globalization is one of the reasons for the growth in infection rate related to travel-
associated gonorrhoea accounting for a high proportion of gonorrhoea cases reported in 
Europe. The reporting showed that 25.5% of the recorded gonorrhea instances were from 
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overseas between 2008 and 2013, mostly in Thailand (31%), followed by the Philippines 
(8%) and Spain (7%) [3].  
2.2. Epidemiology of antimicrobial resistance in Neisseria gonorrhoeae 
In recent decades, N. gonorrhoeae has developed resistance to several antimicrobial classes 
such as sulphonamides, penicillin, tetracyclines, macrolides, fluoroquinolones and, more 
recently, the third-generation cephalosporins [47], Unfortunately, Japan also announced 
that treatment failure with cefixime was reported early [1] [34], similarly treatment failures 
to cefixime and azithromycin in England [15], resistance to cefixime in Austria [44], the 
first cases of Neisseria gonorrhoeae resistant to ceftriaxone in Spain [4], Sweden [12] [41], 
Australia [24] [32], Slovenia [43].  
Unfortunately, multidrug-resistant (MDR) gonococcal strains have substantially increased 
resistance to high-level cefixime and ceftriaxone in France [42].  
In some South-East Asian countries like Vietnam, there have also been reports of resistant 
to azithromycin, 5% to ceftriaxone, and 1% to cefixime [29], in China, the prevalence of 
resistance to azithromycin and decreased susceptibility to ceftriaxone increased 
significantly [55].  
An urgent issue is thought to be serious with the emergence of MDR with high-level 
azithromycin resistance (azithromycin MIC of >256 mg/L), the latest case has been 
recorded in the UK from a heterosexual man who had a regular female sexual partner in 




Figure 3: The percentage of isolates with resistance to azithromycin [48] 
2.3. Solithromycin 
Solithromycin (CEM-101): Solithromycin is a fourth-generation antibiotic of the 
macrolide, which has been considered to treat bacterial community-acquired pneumonia. 
Solithromycin has been studied in clinical isolates since 2009 in the United States and 
Europe [10], and also displayed antimicrobial activity against a diverse collection of Gram-
positive and Gram-negative bacteria [31].  
Solithromycin has shown a high in vitro activity against N. gonorrhoeae reference strains 
and clinical AMR isolates, that is, with MIC50 and MIC90 of 0.064–0.125 mg/L and 
0.125–0.25 mg/L, respectively [11]. Moreover, currently, solithromycin is in phase 3 of 
clinical trials and has been shown to be active in the treatment of gonorrhea. 
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2.4.  Zolifodacin 
Zoliflodacin (ETX0914): As for zoliflodacin, it has a novel action mechanism by which it 
inhibits the Spiropyrimidinetrione topoisomerase. Zoliflodacin is a new 
Spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor with potent in vitro 
antibacterial activity against key Gram-positive (Staphylococcus aureus, Staphylococcus 
epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus 
agalactiae), fastidious Gram-negative (Haemophilus influenzae and Neisseria 
gonorrhoeae), atypical (Legionella pneumophila), and anaerobic (Clostridium difficile) 
bacterial species, including isolates with known resistance to fluoroquinolones [14]. 
Currently, ETX0914 is in phase III RCT, now under final planning, in collaboration 
between the manufacturer Entasis, the Global Antibiotic Research and Development 
Partnerships (GARDP), and WHO. 
III. Methodology 
 
The methods used in this research consist of the following: 
3.1. Collection of clinical Neisseria gonorrhea samples:  
Specimens collected for the discovery of  Neisseria gonorrhea were taken from the genital 
tract and other sites: the rectum, pharynx, and joint fluid. Samples were collected from 
different hospitals all over South Seoul, from January 2016 to December 2018. Moreover, 
patient identification information is hidden in the study according to ethical approval 
required for the present study. 
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3.2. Transporting Neisseria gonorrhea:  
Samples were collected from the patient’s urethra, cervical, rectal, and during the time of 
transport, media is best kept at room temperature and not refrigerated transport to Yonsei 
Severance Hospital [7]. 
3.3. Culture:   
The specimens isolated to be modified by Thayer-Martin media (BBL, Becton Dickinson, 
Cockeysville, MD, USA) consisting of chocolate agar in addition to vancomycin antibiotics 
to the media used to inhibit the growth of Gram-positive bacteria [36]. 
3.4. Identification of Neisseria gonorrhea:  
Inoculated plates incubated at 35±1°C in a 3% to 5% CO2 atmosphere. Colonies of 
Neisseria gonorrhea on chocolate agar appear grey to tan in color, translucent, and raised 
after 24 to 48 hours of incubation, and bacteria grew into colonies with diameters of 1mm, 
opaque, greyish-white, glistening, and convex. At this time, the morphology can be 
observed under the microscope seen, and gram-negative dyeing is also carried out. The 
identification of suspected colonies is confirmed by MALDI-TOT mass spectrometry, by 
allowing for identification of a pathogen in a minute [7]. Neisseria gonorrhea isolates: All 
250 isolates were collected, and samples were stored at Yonsei Severance Hospital to 
conduct similar studies in the future. 
3.5. Antimicrobial susceptibility testing:  
GC agar containing 1% growth supplement is used for disk diffusion testing of Neisseria 
gonorrhea, and also colony suspensions of isolates need to be adjusted to a 0.5 McFarland 
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standard before inoculation onto media [7]. Disk diffusion is one of the classic 
microbiology techniques, with convenience, efficiency, it is chosen as the method for 
determining antimicrobial resistance in this study. MICs of ceftriaxone, spectinomycin, 
penicillin, and ciprofloxacin were determined. Antimicrobial susceptibility testing was 
performed using the agar dilution method according to guidelines published by the CLSI 
[6]. The MIC of cefixime followed the European Committee on Antimicrobial 
Susceptibility Testing [8], in which gentamycin and azithromycin Antibiotic Susceptibility 
Testing was performed by the CDS method [37]. 
The plate was cultured at 36°C with 5% to 10% CO2 for 18 to 24 hours, and the growth of 
gonococci in different concentrations of antibiotics (0.016, 0.032, 0.064, 0.125, 0.25, 0.5, 
1, 2,4, 8, 16, 32, 64 for all antibiotics) was observed and recorded. 
3.6. Molecular epidemiological typing:  
The DNA sequence of isolates was analyzed, to determine the molecular epidemiological 
relatedness, N. gonorrhoeae multiantigen (por and tbpB) sequence typing (NG-MAST) 
was carried out for all isolates (from 2016 to 2017). The sequences data of each por and 
tbpB gene were uploaded to the N.gonorrhoea multi-antigen sequence typing (NG-MAST) 
website (http://www.ng-mast.net/misc/info2.asp) to obtain the sequence type. The por and 
tbpB genes detected in the isolates, and multiplex polymerase chain reactions with two sets 
of primers for por (forward 5’ 350CAA GAA GAC CTC GGC AA366 3', reverse 
5’ 1086CCG ACA ACC ACT TGG T1071 3'), and tbpB (forward 5’ 1098CGT TGT CGG 
CAG CGC GAA AAC 1118 3’, reverse 5’ 1686TTC ATC GGT GCG CTC GCC 
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TTG1666 3’) were performed in 50µl volumes and are carried out in 96 well microtitre 
plates with QIAquick Gel Extraction Kit, using a PTC-200 DNA engine (MJ Research Inc) 
with an initial denaturation at 950C for 4 minutes, followed by 25 cycles of 950C for 30 
seconds, 580C for 30 seconds for por and 690C for tbpB, 720C for 1 minute, followed by 
720C for 10 minutes and cooled to 400C and held. 
Multilocus sequence typing (MLST) performed for all isolates (from 2016 to 2018) that 
showed resistance to at least one of the ESCs examined, followed by guidelines outlined 
on the respective database website (http://pubmlst.org/neisseria/). 
IV. Ethics statement 
The research did not provide demographic information of the patients. Following internal 
sentinel surveillance processes, all gonococcal isolates were grown and stored. This 
research was also given an exemption from the ethics approval requirement because it was 
performed as one of the projects of the national surveillance program supported by the 





Based on historical data, the study isolated the result of increasing the quantity over three 
years. The chart provides the number of isolates in 250 samples from 2016 to 2018, in 
which the case by year is 59, 82, and 109, respectively (Figure 4). As can be seen, this 
result displays the situation of increasing gonorrhea in Korea, 2018 is twice as high as in 
2016. 
 
Figure 4: Distribution of N.gonorrhea isolated from 2016 – 2018 in South Korea 
Table 1 illustrates the susceptibility to novel CEM-101, ETX0914, and antimicrobials 























that MIC of ETX0914 ranges from 0.014 to 0.12 mg/L, in which MIC50 and MIC90 are 0.03, 
0.06 mg/L, respectively. In addition, MIC modal is 0.03 mg/L, from the results of this MIC, 
it can be stated that ETX0914's ability to inhibit bacteria is promising. Similarly CEM-101 
displays MIC range from 014 - 0.5 mg/L, modal MIC is 0.06 mg/L and MIC50 and MIC90 
are 0.06, 0.12 mg/L respectively.  
Representative for ESCs, the figure of ceftriaxone MIC range is 0.007 - 0.5 mg/L, and 
MIC50 and MIC90 are 0.03, 0.12 mg/L respectively. In the same way, the MIC range of 
cefixime is the same as that ceftriaxone. There is a difference in concentration between 
MIC50 compared with MIC90 which are 0.06, 0.25 respectively.  
While the illustration of azithromycin MIC range shows 0.05 – 32 mg/L, MIC50 and MIC90 
are 0.25, 0.5 mg/L, respectively. Another result is that the value of the MIC range of 
spectinomycin is within the acceptable range 8 – 64 mg/L; wherein MIC50, MIC90 had equal 
value (32 mg/L); this indicates that it can still be used for treatment against gonorrhoea.   
The table also noted penicillin, tetracycline, and ciprofloxacin had antimicrobial resistance, 
it can be seen that particular: penicillin MIC range is 0.06 - 129 mg/L, and MIC50 and MIC90 
are 2, 16 mg/L respectively. Tetracycline MIC range is 0.12 - 129 mg/L, and MIC50 and 
MIC90 are 4, 64 mg/L respectively. Similarly, the MIC of ciprofloxacin range is 0.05 - 









Table 1: Susceptibility to novel CEM-101, ETX0914, and antimicrobials previously and 
currently used for the treatment against NG in 250 isolates from 2016-2018 in Korea 
Antimicrobial 
MIC (mg/L) MIC break-points (mg/L) 
Range 50% 90% I R 
ETX0914 0.014 - 0.12 0.03 0.06 ND ND 
CEM-101 0.014 - 0.5 0.06 0.12 ND ND 
PEN 0.06 - 129 2 16 0.12 - 1 ≥ 2 
CRO  0.007 - 0.5 0.03 0.12 - - 
CFX1 0.007 - 0.5 0.06 0.25 - >0.125 
SPT 8 - 64 32 32 64 ≥ 128 
GM2 0.25 - 32 4 8 8-16 >16 
TET 0.12 - 129 4 64 0.5 - 1 ≥ 2 
CIP  0.05 - 64 8 16 0.12 - 0.5 ≥ 1 
AZTH2 0.05 - 32 0.25 0.5 - ≥ 1 
ETX0914: Zoliflodacin; CEM-101: solithromycin; PEN: penicillin; CRO: ceftriaxone; CFX: cefixime;  
SPT: spectinomycin; GM: gentamycin; TET: tetracycline; CIP: ciprofloxacin; AZTH: azithromycin. 
1: European Committee on Antimicrobial Susceptibility Testing   
2: Antibiotic Susceptibility Testing By The CDS method 
ND: not determined 




Table 2 showed the proportion of the difference between medicine susceptibility test 
results, high, and intermediate level resistance, among eight antibiotics done on 250 
isolates. Over the years from 2016 – 2018, the high-proportion of resistance to both 
ciprofloxacin and tetracycline are 94.8%, 78.8%, respectively. Particular by year with 
ciprofloxacin, which are 98.3%, 98.8%, 89.9%, respectively. The same with tetracycline, 
which is 79.7%, 79.3%, and 78%%, respectively.  
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The results also displayed that ciprofloxacin and tetracycline susceptibility level was low, 
under 10% in all three years, that account for the non-use of these antibiotics in the 
treatment of gonorrhea. Intermediate level in penicillin accounted for exceeding 43% 
among the samples isolated from 2016 to 2018 were 44.1%, 43.9%, and 54%, respectively, 
without the appearance of medicine- susceptibility isolation in penicillin. 
Susceptibility, according to table 2, shows no drug resistance observed for ceftriaxone, only 
0.4% was intermediate level over three years, remaining the isolated samples remained 
susceptibility to ceftriaxone, the proportion in turn over the years was 100%, 98.8%, and 
100%, respectively.  
Similarly, the results also displayed that spectinomycin also has a 98.8% susceptibility 
level among the samples isolated through the years, in 2017 susceptibility level was 96.3%, 
no resistance in spectinomycin is isolated from 2016-2018.  
It is noticeable that the proportion of resistance to cefixime exceeded 33% over three years, 
in which the proportion of resistance was 37.3%, 31.7%, and 25%, respectively. 
Meanwhile, for azithromycin, the sample isolated in 2017 did not detect drug resistance 
level, however, the year 2016 and 2018, the percentage of the isolated form of drug 
resistance level was slightly higher (3.4%) and 13.8%, respectively. 
Besides, gentamycin did not have resistance levels in samples that are isolated. Although 
the trend, the proportion of gentamycin was high susceptibility, intermediate level, namely, 
2016 year is 45.8%, expanding to 63% in 2018. 
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Table 2: Susceptibility to antimicrobials previously and currently used for the treatment 
of gonorrhea in 250 isolated in South Korea. 
Antimicrobials 
S/I/R (%) 
2016 2017 2018 Total 
PEN 0/44.1/55.9 0/43.9/56.1 0.9/54.1/45 0.4/48.4/51.2 
CRO 100/0/0 98.8/1.2/0 100/0/0 99.6/0.4/0 
CFX1 62.7/0/37.3 68.3/0/31.7 67/0/23 66.4/0/33.6 
SPT 100/0/0 96.3/3.7/0 100/0/0 98.8/1.2/0 
GM2 54.2/45.8/0 73.2/26.8/0 36.1/63/0.9 52.6/47/0.4 
TET 0/20.3/79.7 6.1/14.6/79.3 1.8/20.2/78 2.8/18.4/78.8 
CIP 1.7/0/98.3 1.2/0/98.8 3.7/6.4/89.9 2.4/2.8/94.8 
AZI2 96.6/0/3.4 100/0/0 86.2/0/13.8 93.2/0/6.8 
ETX0914: zoliflodacin; CEM-101: solithromycin; PEN: penicillin; CRO: ceftriaxone; CFX: cefixime;  
SPT: spectinomycin; GM: gentamycin; TET: tetracycline; CIP: ciprofloxacin; AZTH: azithromycin. 
1: European Committee on Antimicrobial Susceptibility Testing   
2: Antibiotic Susceptibility Testing By The CDS method 
S: susceptibility, I: intermediate, R: resistance 
                                                     • 
 
The Table 3 showed the MIC distributions for solithromycin, zoliflodacin, the penicillin, 
ceftriaxone, cefixime, spectinomycin, gentamycin, tetracycline, ciprofloxacin, 
azithromycin (Figure 5 and Table 3), of which penicillin (51.2%), tetracycline (78.8%) and 
ciprofloxacin (94.8%) are fully resistant to the treatment of gonorrhea, besides 
azithromycin has also developed resistance (17 cases), similar to cefixime. More than 1/3 
(84 cases) of isolated samples also developed resistance. 
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In this study, the antibiotics currently used to treat gonorrhea are still susceptible to the 
gonorrhea bacteria, particular: azithromycin (93.2%), spectinomycin (100%), ceftriaxone 
(100%), cefixime (66.4%). Only ciprofloxacin (94.8%), tetracycline (78.8%), penicillin 
(51.2%) were resistant to N. gonorrhea. 
The MIC distribution for zoliflodacin is less than 0.25 mg/L, of which less than 78% or 
equal to 0.032 m /L, the result is close to 0. Similarly, most of MICs ceftriaxone is less than 
or equal to 0.125 mg/L while distributive cefixime is discrete. A slight difference in MIC 
distribution for solithromycin was around over 2.8% samples higher than 0.125mg/L. 
Overall, the MIC range of antimicrobials (ETX, SOL, CRO, and CFX) had from 0.016-
0.125 mg/L.  
 
Table 3: MIC (mg/liter) distributions for ETX0914, AZTH, CFX, CIP, CRO, GM, SOL, 





0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16 32 64 
ETX 57 139 44 10          
SOL 59 60 104 20 6 1        
PEN   1 12 23 29 57 65 26 7 30   
CRO 77 50 64 40 18 1        
CFX 72 35 27 32 59 25        
SPT            247 3 
GM     1 2 3 27 98 109 8 1  
TET    5 2 24 22 53 20 7 117   
CIP   6  4 3 17 20 39 54 82 19 6 
AZTH   45 59 74 55 14 1   2   
 ETX0914: zoliflodacin; CEM-101: solithromycin; PEN: penicillin; CRO: ceftriaxone; CFX: cefixime;  
SPT: spectinomycin; GM: gentamycin; TET: tetracycline; CIP: ciprofloxacin; AZTH: azithromycin. 




Herein, both zoliflodacin and solithromycin were diluted in cell culture medium and tested 
at concentrations ranging from 0.016 to 16mg/L, the inhibitory concentration of 
zoliflodacin and solithromycin is nearly zero value, which suggests that the effectiveness 
of testing isolates is extremely susceptible to both antibiotics. The correlation coefficient 
between the MICs of zoliflodacin and ciprofloxacin in 250 isolates was - Coefficient of 
correlation Spearman’s: 0.437 (p<0.05). This means there are no associations between the 
MICs of zoliflodacin and the previously used DNA gyrase/topoisomerase IV inhibitor 
fluoroquinolone ciprofloxacin or there were no cross-resistance between zoliflodacin and 
ciprofloxacin.  
 
On the by hand, between the two drug groups of the same generation, experiments on 
isolated samples also showed that the inhibitory concentration of solithromycin is much 
less than that of azithromycin, the coefficient of correlation was – Coefficient of correlation 
Spearman’s: 0.745 (p<0.05). This correlation may be related to the gonorrhea strains 




ETX0914: zoliflodacin; CEM-101: solithromycin; PEN: penicillin; CRO: ceftriaxone; CFX: cefixime;  
SPT: spectinomycin; GM: gentamycin; TET: tetracycline; CIP: ciprofloxacin; AZTH: azithromycin 
Figure 5: MIC (mg/liter) distributions for ETX0914, AZTH, CFX, DIP, CRO, GM, SOL, 
SPT, TET in 250 isolated in South Korea 
Figure 6 illustrates of the molecular epidemiology of the 240 N.gonorrhoea isolates 
sequence type detected from 2016 to 2018, the majority of MLST are ST1901 (71), ST1588 
(68), ST7823 (21), ST1759(9) and a few other sequence types are detected but in small 
numbers, and three new strains NEW-1(8), NEW-2(1), NEW-3(1) were also identified.  
An analysis of N.gonorrhoea isolates MLST STs over the years observed eight STs (1901, 
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NEW-1, 1579, 1583, 9362, 8780, 1596, 7367, 8143), and twenty-five STs (didn’t show in 
Table 4), respectively (Table 4). In which the number MLST ST1588 increased more than 
two times in 2016. The remaining strains did not show any abnormal increase, cover newly 
discovered strain. 
 
Figure 6: Distribution of isolates by sequence type of  MLST from 2016 – 2018 in South 
Korea 
 
The six strains found in 2016 were observed again in 2017, 2018 (Table 4). Given that 
these strains are still circulating in the community, some other strains were found to have 
no overlap that could indicate the circulation from different places, is possible. This 
evidence study showed that ST1901, ST1588, ST7823, ST7363 are the most common and 
genetically closely related ST for three years. A new strain is inherited for more than two 



























Table 4: Comparison of molecular typing MLST and NG-MAST of specimens positive 
with Neisseria Gonorrhoeae by year, South Korea. 
Year 
MLST ST  
(No. 
specimens) 




10668 (7), 11497 (4), 2958 (2), 14678 (2), 14673 (1), 14671 (1), 
11495 (1), 7309 (1), 14672 (1), 14676 (1), 14675 (1), 15097 (1), 
7307 (1), 14662 (1), 15098 (1), 14666 (1), 14667 (1) 
1588 (8) 
3611 (2), 14668 (1), 14661 (1), 5576 (1), 14674 (1), 6696 (1), 
12399 (1) 
7363 (3) 6910 (2), 10216 (1) 
NEW-1 (3) 7304 (2), 14664 (1) 
1579 (1) 8044 (1) 
7822 (3) 14663 (1), 14670 (1), 14665 (1) 
1596 (1) 6696 (1) 
11431 (1) 14669 (1) 
2017 
1901 (24) 
15014 (6), 14678 (5), 15019 (1), 4500 (1), 16244 (1), 7307 (1), 
15016 (1), 7309 (1), 15866 (1), 11497 (1), 16247 (1), 16270 (1), 
16271 (1), 4431 (1), 2958 (1) 
1588 (21) 
15024 (8), 14668 (3), 16267 (1), 13411 (1), 16262 (1), 16263 (1), 
16264 (1), 16265 (1), 16266 (1), 16255 (1), 3611 (1), 16261 (1) 
7823 (11) 16250 (5), NEW (2), 16274 (1), 16275 (1), 16245 (1), 16251 (1) 
7363 (3) 5308 (1), 16272 (1), 6910 (1) 
NEW-1 (4) 7304 (2), 16280 (1),  16243 (1) 
1579 (3) 8044 (1), 16254 (1), 16203 (1) 
1583 (1) 12535 (1) 
9362 (1) 16278 (1) 
8780 (1) 16277 (1), 15070 (1) 
1596 (1) 16268 (1) 
7367 (1) 16248 (1) 




These circulating strains have a high proportion of antibiotic resistance (Table 5), 
particularly such as ST1901, which is resistant to ciprofloxacin (28.4%), tetracycline 
(21.2%), penicillin (16.8%), cefixime (12.4%), and also azithromycin (3.6%). A second 
common strain ST1588 also had a very high resistance rate, namely ciprofloxacin 
resistance (26.4%), tetracycline (26.4%), penicillin (10.8%), cefixime (13.2%). The NEW-
1 strain was resistant to cefixime and azithromycin, while the NEW-2 strain and NEW-3 
were not (Table 5). 
 




No. of resistant isolates 
PEN CRO CFX SPT GM TET CIP AZTH 
1901 71 42 0 31 0 1 53 71 9 
1588 68 27 0 33 0 0 66 67 0 
7823 21 14 0 0 0 0 18 18 0 
7363 12 10 0 8 0 0 8 12 1 
NEW-1 8 2 0 1 0 0 7 8 1 
1579 9 1 0 5 0 0 8 9 3 
1583 5 0 0 0 0 0 1 2 0 
9362 5 1 0 1 0 0 1 3 0 
7822 4 1 0 0 0 0 3 4 0 
8780 3 3 0 0 0 0 0 3 0 
1596 2 0 0 0 0 0 2 2 0 
1600 2 1 0 0 0 0 2 2 1 
7367 2 0 0 0 0 0 2 0 0 






No. of resistant isolates 
PEN CRO CFX SPT GM TET CIP AZTH 
8143 2 2 0 0 0 0 0 2 0 
8774 2 0 0 0 0 0 2 2 0 
11431 2 2 0 0 0 0 0 2 0 
NEW-2 1 0 0 0 0 0 1 1 0 
NEW-3 1 1 0 0 0 0 0 1 0 
PEN: penicillin; CRO: ceftriaxone; CFX: cefixime; SPT: spectinomycin; GM: gentamycin; TET: tetracycline;  
CIP: ciprofloxacin; AZTH: azithromycin 






N. Gonorrhoeae has consistently shown extreme ability to create resistance to all 
antimicrobials introduced for therapy, and remains one of the world's most prevalent 
sexually transmitted diseases (STDs). Emerging multi-drug resistant N. Gonorrhoea 
affects global therapy for gonorrhea, a significant public health concern. Dual antibacterial 
therapy for treatment is currently used in many nations. The suggested dual treatment has 
a high rate of success but may have contributed to the international reduction of ESC 
resistance [13] [21] [40]. This study observed that, penicillin, tetracycline, ciprofloxacin 
was resistant and, in the world today, these three drugs are entirely resistant to gonorrhea, 
and it has been eliminated from the gonorrhea treatment program by WHO. 
On the by hand, our isolates identified and conducted MIC with ESCs, in which ceftriaxone 
resistance was not detected, but there were some resistant strains of ESCs - cefixime 
(33.6%) and azithromycin (6.8%) – this cutoff is considered to have started a resistance. In 
Canada, the government's announcement that antibiotics should not be used to treat 
gonorrhea if the prevalence of resistance to that antibiotic exceeds 3% [33]. Among ESCs, 
oral cefixime and injected ceftriaxone is recommended for the treatment of gonorrhea 
internationally, but most likely caused a treatment failure with cefixime was reported first 
in Japan [1] [34] thereafter cefixime was no longer recommended as a treatment option in 
Japan, and cefixime resistance was subsequently reported in many countries around the 
globe such as France [42], and Austria [44]. Currently, new research in Japan also 
accounted for the proportion of gonococci that reduce susceptibility or resistance to 
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ceftriaxone has increased, from 2.5% to 4.0%; besides an increase in azithromycin from 
0% to 14.5% was also detected, however, this increase was not significant [34]. A 
significant increase in resistance of cefixime from 18.0% in 1996-2005 to 46.0% in 2008-
2016 in Japan has also been reported [34]. In Korea, there were also studies on isolated 
samples from 2000 - 2006 where ESCs - cefixime resistant strains also appeared but not 
significant, with only 1/977 isolates [17], resistance to cefixime has also been reported in 
subsequent years but in small percentage [20]. The warning of ESCs resistance in South 
Korea has also been early, in-depth studies of molecules and mutations have been 
conducted [18] [20] [19]. The discovery of the resistance mechanism of N. gonorrhoeae 
has helped the world to have a better understanding view of the cause of  N. gonorrhoeae 
resistance, helping to invent new drugs in the future that can better treat gonorrhea 
(Appendix 1). 
In response to this need, we evaluated the antimicrobial activity of CEM-101 and ETX0914 
against N. gonorrhoea. Herein, the study showed that zoliflodacin and solithromycin are 
significantly more active against N. gonorrhoea isolates and superior to that of other 
antimicrobials currently or previously recommended for gonorrhea treatment. The MIC 
distribution for ETX0914 appeared to represent mainly a wild-type MIC distribution,  as 
well as no cross-resistance between ETX0914 and ciprofloxacin (also a topoisomerase II 
inhibitor). In comparison, all MIC of isolates were less than 0.25 mg/L and displayed high 
potency against isolates.  
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It is related to ETX0914 of MIC distribution of CEM-101 <0.5mg/L is also much lower 
than the other antibiotics tested with it. Only one isolate (0.4%) MIC of solithromycin (0.5 
mg/mL) has been confirmed by MLST (ST1600), which is resistant to azithromycin. In 
short, in vitro antimicrobial susceptibility results for both CEM-101 and ETX0914 
demonstrate better activity compared with azithromycin, ceftriaxone, which first-line 
treatment of N. gonorrhoeae. 
For all isolates with in vitro resistance to cefixime (n=84; 33.6%), and azithromycin (n=17; 
6.8%) the MIC50, MIC90 of solithromycin were 0.06 mg/L, 0.12mg/L, respectively. 
Similarly zoliflodacin were 0.03mg/L, 0.06mg/L, respectively. The findings of this 
research were consistent with that of earlier smaller studies that examined the susceptibility 
of ETX0914 and CEM-101 among N. gonorrhoeae isolates [46] [26], the breakpoint was 
suggested with both MICs <0.25mg/L susceptible in this study. Asserting that, evidence 
from previous clinical trials and in vitro isolates has shown that both zoliflodacin and 
solithromycin might be an effective treatment option for gonorrhea in the future, 
specifically solithromycin is more potent than azithromycin against gonococcal strains. 
Multi-locus sequence typing investigation and relationship between MLST and 
cephalosporin resistance: Molecular typing of gonococci circulating in South Korea were 
also found in the isolates of this study [21]. Genetic strains such as ST1901 and ST1588 
displayed resistance to cefixime of 12.4% and 13.2%, respectively. Discover the prevalence 
of antibiotic-resistant gonococci, and molecular mechanisms of ESC resistance, antibiotic 
susceptibility and molecular characteristics of N. gonorrhoeae strains showed a significant 
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increase in susceptibility or resistance to cefixime (33.6%) and resistance to ciprofloxacin 
(94.4%) and azithromycin (14.5%) detected among gonococcal strains obtained from 2016 
2018. Failure of ceftriaxone treatment has also been identified worldwide, with evidence 
of MLST ST1901 reported in Sweden [41] [12], Australia [24] [32], Slovenia [43], 
although we have not observed it in vitro in this time. 
N. gonorrhoeae multiantigen sequence typing analysis and relationship between NG-
MAST and MLST: In recent years, NG-MAST ST15024, ST10668, ST14678, ST15014, 
ST11497, ST16250 have been a prevalent ST in South Korea, and this ST has also 
accounted for a substantial proportion of the decreased susceptibility and resistance to 
ESCs in  South Korea [21]. In this study, a total of 131 NG-MAST STs were identified 
among the 250 isolates from 2016 to 2018 and three new strains were detected. ST15024, 
ST10668, ST14678 were the most prevalent NG-MAST ST while the first NEW strain is 
related to por8724, tbpB445, the second NEW strain is related to por1494, tbpB110. Both 
strains are still susceptible to cefixime and ceftriaxone, and there was not any difference 
between por alleles, tpbB alleles, and MLST ST among the most common NG-MAST. 
Antimicrobial resistance (AMR) in bacterial pathogens has become one of the most critical 
public health threats worldwide, not for gonorrhea but for all other infectious diseases. 
Morbidity and mortality rates are high. A comprehensive antibiotic resistance surveillance 
program will help reduce morbidity, mortality, prolong life, and reduce treatment costs, 




- Continue to maintain essential surveillance for gonorrhea as a response to global 
health security goals. 
- Currently approved treatments of double antibacterial therapy (250 mg of 
ceftriaxone plus 1g of azithromycin or 250 mg of ceftriaxone plus 100 mg of 
doxycycline twice daily for 7 days) can still respond well to treatment for patients. 




The in vitro susceptibility to zoliflodacin and solithromycin were examined  N. 
gonorrhoeae isolates (n=250) from 2016 to 2018. These in vitro outcomes indicate that for 
close future gonorrhea therapy, zoliflodacin and solithromycin may be efficient 
antimicrobials. Results of the MICs indicated a wild-type distribution primarily and 
compared in vitro activity against gonococcal isolates that are prone and resistant to 
ciprofloxacin, ceftriaxone, cefixime and azithromycin, the first line of which is gonorrhea 
therapy. There were no cross-resistance between zoliflodacin and ciprofloxacin (also a 
topoisomerase II inhibitor) or ones previously used for the treatment of gonorrhea. 
However, cross-resistance between azithromycin and solithromycin has been illustrated. 
Additional research on N. gonorrhea also confirms the results of the recently completed 
phase 3 trial in vitro/pharmacokinetics in humans. Nevertheless, it should be noted that the 
recently completed Phase III clinical trial for solithromycin has identified relatively many 
treatment failures. Zoliflodacin is more promising, and a multi-continental Phase III 
clinical trial will begin in 2019, which would be highly valuable. 
ESC's resistance is also a focus on the treatment of gonorrhea. Although ceftriaxone-
resistant N. gonorrhoea isolates have not yet appeared, more than one-third of the isolates 
were resistant to cefixime. These strains have a very close genetic relationship with the 
current common strains. Three new strains were detected in N. gonorrhoea isolates, of 
which one was resistant to azithromycin. With the current first-line treatment regimen, it is 
likely that in the future, there will be more strains resistant to azithromycin, and the need 
to find new alternatives is urgent. 
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Appendix 1: Antimicrobial resistance determinants in Neisseria gonorrhoeae for 
antimicrobials used for treatment of gonorrhea [47] 
Antimicrobial Resistance determinants/mechanisms 
Ceftriaxone, 
cefixime 
– Mosaic penA alleles: encode mosaic PBP2s with decreased PBP2 acylation 
rate. Mosaic PBP2s amino acid substitutions confirmed to contribute to resistance 
are A311V, I312M, V316T, V316P, T483S, A501P, A501V, N512Y, and G545S 
– penA SNPs: A501Vand A501T in nonmosaic penA alleles can increase the 
MICs of ESCs. Also G542S, P551S, and P551L have been statistically associated 
with elevated MICs ofESCs; however, their effects on resistance have not been 
proven with, for example, site-directed penA mutants into isogenic backgrounds 
– Mosaic mtr locus or mtrR mutations, in promoter (mainly a single nucleotide 
(A) deletion in the 13-bp inverted repeat sequence) or coding sequence (most 
common being a G45D amino acid substitution), that cause an overexpression and 
enhanced efflux of the MtrCDE efflux pump 
– porB1b SNPs: for example, G120Kand G120D/A121D in loop 3 ofPorB1b that 
decrease influx (penB resistance determinant). The penB phenotype appears only 
expressed in gonococcal strains that express also the mtrR resistance determinant 
– “Factor X”: unknown nontransformable penicillin and ESC resistance 
determinant 
Azithromycin 
– SNPs in the 23S rRNA gene (in 1–4 ofthe four alleles) that encodes 23S rRNA 
(peptidyltransferase loop ofdomain V) with decreased affinity to the 50S 
ribosomal target for azithromycin. The SNPs C2611T and A2059G cause low-
level and high-level resistance, respectively; however, the number of mutated 
alleles is correlated with the MICs of azithromycin 
– mtrR mutations: see above  
– erm genes (ermB, ermC, and ermF): acquired from other bacterial species and 
encode rRNA methylases that can methylate nucleotides in the 23S rRNA 
azithromycin target 
– MacAB efflux pump: overexpression can elevate the MICs of azithromycin – 
mef-encoded efflux pump: acquired from other bacterial species and export 
macrolides out of the bacterial cell and elevate the MICs of macrolides 
Spectinomycin 
– 16S rRNA SNP: C1192U in the spectinomycin-binding region of helix 34 that 
decreases affinity to ribosomal spectinomycin target 
– rpsE mutations (encoding the 30S ribosomal protein S5): resulting in amino 
acid alterations such as T24P, deletion of V25, and K26E, which disrupt the 
spectinomycin binding to ribosomal target 
Ciprofloxacin, 
ofloxacin 
– gyrA SNPs: for example, S91F, D95N, and D95G in the QRDRthat decrease 
the fluoroquinolone binding to the GyrA subcomponent of DNA gyrase 
– parCSNPs: for example, D86N, S88P, and E91K in the QRDRthat decrease the 
fluoroquinolone binding to the ParC subcomponent of topoisomerase IV 
PBP2 penicillin-binding protein 2 (PBP2), MIC minimum inhibitory concentration, ESCs extended-
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